✨ Medicines Distribution Consents
11 NOVEMBER NEW ZEALAND GAZETTE 3989
Active Ingredient(s): Amoxycillin (trihydrate) 29.5 mg/mL equivalent to 25 mg/mL amoxycillin.
Potassium clavulanate 15.55 mg/mL equivalent to 6.25 mg/mL clavulanic acid.
Dosage Form: Powder for oral suspension.
NZ Sponsor: Douglas Pharmaceuticals Limited.
Manufacturer(s): Ranbaxy Laboratories Limited, Dewas, Madhya Pradesh, India.
Product: Synermox Syrup 250.
Active Ingredient(s): Amoxycillin (trihydrate) 59 mg/mL equivalent to 50 mg/mL amoxycillin.
Potassium clavulanate 31.1 mg/mL equivalent to 12.5 mg/mL clavulanic acid.
Dosage Form: Powder for oral suspension.
NZ Sponsor: Douglas Pharmaceuticals Limited.
Manufacturer(s): Ranbaxy Laboratories Limited, Dewas, Madhya Pradesh, India.
Dated this 4th day of November 1999.
S. S. JESSAMINE, Acting Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go8206
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Stocrin.
Active Ingredient(s): Efavirenz 100 mg.
Dosage Form: Capsule.
NZ Sponsor: Merck Sharp & Dohme (New Zealand) Limited.
Manufacturer(s): Du Pont Merck Pharmaceuticals Co., Garden City, New York, United States of America.
Product: Stocrin.
Active Ingredient(s): Efavirenz 200 mg.
Dosage Form: Capsule.
NZ Sponsor: Merck Sharp & Dohme (New Zealand) Limited.
Manufacturer(s): Du Pont Merck Pharmaceuticals Co., Garden City, New York, United States of America.
Product: Stocrin.
Active Ingredient(s): Efavirenz 50 mg.
Dosage Form: Capsule.
NZ Sponsor: Merck Sharp & Dohme (New Zealand) Limited.
Manufacturer(s): Du Pont Merck Pharmaceuticals Co., Garden City, New York, United States of America.
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 4th day of November 1999.
S. S. JESSAMINE, Acting Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go8207
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the act and are set out in the Schedule hereto:
Schedule
Product: Nasonex.
Active Ingredient(s): Mometasone furoate monohydrate 51.7 µg/dose equivalent to 50 µg/dose mometasone furoate.
Dosage Form: Nasal spray solution.
NZ Sponsor: Schering-Plough Pty Limited.
Manufacturer(s): Schering-Plough Laboratoires NV, Heist-op-den-Berg, Belgium.
Schering-Plough Products Inc, Manati Operations, Manati, Puerto Rico.
Product: Rhinax.
Active Ingredient(s): Mometasone furoate monohydrate 51.7 µg/dose equivalent to 50 µg/dose mometasone furoate.
Dosage Form: Nasal spray solution.
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1999, No 168
NZLII —
NZ Gazette 1999, No 168
✨ LLM interpretation of page content
🏥
Consent to Distribution of New Medicines
(continued from previous page)
🏥 Health & Social Welfare4 November 1999
Medicines Act 1981, New medicine, Distribution consent, Pharmaceuticals
- S. S. Jessamine, Acting Chief Advisor, Safety and Regulation
🏥 Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare4 November 1999
Medicines Act 1981, Provisional consent, New medicine, Pharmaceuticals
- S. S. Jessamine, Acting Chief Advisor, Safety and Regulation
🏥 Consent to the Distribution of Changed Medicines
🏥 Health & Social Welfare4 November 1999
Medicines Act 1981, Changed medicine, Distribution consent, Pharmaceuticals
- S. S. Jessamine, Acting Chief Advisor, Safety and Regulation